Amphotericin B and Ganciclovir Interaction

Understanding the Amphotericin B and Ganciclovir Interaction

FDA-approved prescribing information for these two drugs flags their combination as a moderate-severity interaction. Amphotericin B belongs to the Polyene Antifungal class and Ganciclovir belongs to the Antiviral (Nucleoside Analog) class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Both of these medications can be toxic to the kidneys when used at the same time. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Amphotericin B has 12 total documented interactions on file in this dataset, and Ganciclovir has 9. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Your doctor will need to check your kidney function frequently while you are on both drugs. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Amphotericin B or Ganciclovir based on a web page, speak with your prescriber or pharmacist before making any change.